Akari Therapeutics Plc (AKTX) - News Archive

In recent years, Antibody-Drug Conjugates (ADCs) have emerged as a promising therapeutic modality in oncology, offering targeted drug delivery combining the specificity of antibodies with the cytotoxic potency of chemot...

Akari Therapeutics: A Financial Rebirth Amidst Challenges in the Biopharmaceutical LandscapeOverview of Recent DevelopmentsAkari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company specializing in innovative therap...

Akari Therapeutics Regains Full Nasdaq Compliance and Secures Financing Amid Shareholder Support for Peak Bio MergerAkari Therapeutics Plc, a clinical-stage biopharmaceutical company known for its innovative therapies t...

Breaking News: Akari Therapeutics Secures $3.2 Million in PIPE Financing Date: November 8, 2024 In a pivotal development for the pharmaceutical industry, Akari Therapeutics Plc (NASDAQ: AKTX) announced today that it has...

Breaking News: Akari Therapeutics and Peak Bio Merger Receives Overwhelming Shareholder SupportBOSTON and LONDON, Nov. 8, 2024 — In a significant leap forward for the biotechnology sector, Akari Therapeutics, Plc (Nasda...

Breaking News BOSTON and LONDON, Oct. 15, 2024 — In a significant development for the biotechnology sector, Akari Therapeutics, Plc (Nasdaq: AKTX) has announced the effectiveness of its Form S-4, originally filed with t...

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with ShareholdersAkari Therapeutics Reports Second Quarter 2024 Financial Results and Recent HighlightsIn a recent turn...

Geographic atrophy (GA), a progressive retinal degenerative disorder, represents a significant cause of vision loss in the aging population. The recent pre-Investigational New Drug (pre-IND) meeting between Akari Therap...

In a world gripped by economic uncertainty and geopolitical tensions, the healthcare sector continues to demonstrate its resilience and potential for growth. Within the Biotechnology & Medical Research industry, one nam...

In a recent announcement, biotechnology company Akari Therapeutics Plc (Nasdaq: AKTX) has provided details about the employment contract of its newly appointed Interim President & CEO, Dr. Samir R. Patel. The contract r...

Akari Therapeutics Plc Secures $7.6 Million in Successful Initial Closing of Private Placement Financing RoundIn recent news, Akari Therapeutics Plc, a biotechnology company focusing on therapies for autoimmune and infl...

Breaking News: Akari Therapeutics and Peak Bio Prioritize ADC Technology and GA Program in Groundbreaking MergerBOSTON and PLEASANTON, Calif., May 01, 2024 – Akari Therapeutics, Plc (Nasdaq: AKTX, Akari) and Peak Bio In...

BOSTON and PLEASANTON, Calif., March 05, 2024 - Akari Therapeutics, Plc (Nasdaq: AKTX) and Peak Bio Inc. (OTC: PKBO) have officially announced their agreement to merge as equals in an all-stock transaction. This strateg...

Akari Therapeutics Announces $2 Million Private Placement Financing with Existing InvestorsBoston and London, Jan. 02, 2024 - Akari Therapeutics, a leading biotechnology company focused on advanced therapies for autoimm...